Month: February 2021

Chicago, IL, Feb. 18, 2021 (GLOBE NEWSWIRE) — FOMO CORP. (“FOMO”) has replied to FINRA’s third round of comments on its application to change its name with FINRA to “FOMO CORP.” and ticker to “FOMO”. The Company’s transfer agent Signature Stock Transfer has similarly replied on their end. The Company changed its legal name with the Secretary of State of California on December 16, 2019 and with the SEC’s EDGAR system shortly thereafter. A new CUSIP number has been obtained as part of the process. Management is confident it has addressed FINRA’s requests for information following the application for said name change / ticker change on November 17, 2020, though there are no assurances on timing. Management believes the name reflects the Company’s growth prospects in public venture capital investments.About FOMO CORP.FOMO CORP. is a publicly...

GREENVILLE, S.C., Feb. 18, 2021 (GLOBE NEWSWIRE) — United Community Banks, Inc. (NASDAQ: UCBI) (“United”), reported that its Board of Directors approved an increase of its regular quarterly cash dividend to $0.19 per share on the Company’s common stock. The dividend is payable April 5, 2021 to shareholders of record as of March 15, 2021. This represents a 5.6% increase over the quarterly dividend in the last five quarters.The Board of Directors also approved a quarterly cash dividend of $429.6875 per share (equivalent to $0.4296875 per depositary share or 1/1000th interest per share) on the Company’s 6.875% Non-Cumulative Perpetual Preferred Stock, Series I (NASDAQ: UCBIO). The dividend is payable March 15, 2021 to shareholders of record on February 28, 2021.About United Community Banks, Inc.United Community Banks, Inc. (NASDAQ:...

SAN ANTONIO, Feb. 18, 2021 (GLOBE NEWSWIRE) — CloudCommerce, Inc. (CLWD), a leading provider of digital advertising solutions, today announced that it has entered into a license agreement with WRENCH.AI to use its AI-driven customized personalization engine to enhance the Company’s AI-enabled SWARM platform. Adding this critical component will allow the Company to speed the development of SWARM to dramatically reduce the cost of advertising.“Using machine learning and artificial intelligence, WRENCH.AI makes it easier for advertisers to harness the power of their data to automate the process of creating personas to optimize marketing and advertising efforts,” said Andrew Van Noy, the Company’s CEO. “Our licensing agreement with WRENCH.AI, will allow us to further develop SWARM to integrate with customer relationship management (CRM)...

Additional information available in the attached documents.Contacts:VALMIERAS STIKLA ŠĶIEDRA, ASPhone: +371 64202216E-mail: latvia@valmiera-glass.comWeb: www.valmiera-glass.comAttachmentsNotification P-D Aircraft Composites ENNotification P-D Glasseiden Oschatz ENNotification P-D Management Industries Technologies ENNotification Stefan Allexander Preiss-Daimler EN

Papildu informācija pievienotajos dokumentos.Kontaktinformācija:AS VALMIERAS STIKLA ŠĶIEDRATel.: +371 64 20 22 16E-pasts: latvia@valmiera-glass.comMājaslapa: www.valmiera-glass.comPielikumiNotification P-D Aircraft Composites LVNotification P-D Glasseiden Oschatz LVNotification P-D Management Industries Technologies LVNotification Stefan Allexander Preiss-Daimler LV

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTORONTO, Feb. 18, 2021 (GLOBE NEWSWIRE) — SOLAR ALLIANCE ENERGY INC. (TSXV: SOLR) (the “Company” or “Solar Alliance”) is pleased to announce it has closed the marketed private placement of 13,696,500 units of the Company (“Units”) at $0.42 per Unit for gross proceeds of $5,752,530 previously announced on January 29, 2021 and February 5, 2021 (the “Offering”).The Offering was led by Echelon Wealth Partners Inc. (“Echelon”) and a syndicate of agents appointed by Echelon (the “Agents”). Pursuant to the agency agreement entered into by the Company and the Agents in connection with the Offering, the Company has granted the Agents an option to purchase up to an additional 15% of the Offering in Units (“Agents’ Option”). The Agents have exercised...

THIS ANNOUNCEMENT, INCLUDING THE APPENDICES AND THE INFORMATION CONTAINED THEREIN, IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE, DISTRIBUTION OR FORWARDING, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER OF SECURITIES IN ANY JURISDICTION. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.LONDON, Feb. 18, 2021 (GLOBE NEWSWIRE) — Horizonte Minerals Plc (AIM: HZM, TSX:HZM)...

Phase 2/3 trial will enroll approximately 4,000 healthy pregnant women in the U.S., Canada, Argentina, Brazil, Chile, Mozambique, South Africa, U.K., and SpainFirst participants dosed in the U.S.  Women enrolled in the trial will be unblinded shortly after giving birth to allow those women who originally received placebo to be vaccinated while staying in the studyNew York, USA and Mainz, Germany, February 18, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in a global Phase 2/3 study to further evaluate the safety, tolerability, and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in preventing COVID-19 in healthy pregnant women 18 years of age and older.   “We are proud to start this study in pregnant women and continue to gather the evidence on...

Phase-2/3-Studie wird ca. 4.000 gesunde, schwangere Frauen in den USA, Kanada, Argentinien, Brasilien, Chile, Mosambik, Südafrika, dem Vereinigten Königreich und Spanien umfassenErste Teilnehmerinnen wurden in den USA bereits geimpftStudienteilnehmerinnen werden kurz nach der Geburt entblindet, um auch Frauen in der Placebo-Gruppe eine Impfung zu ermöglichen, während sie weiterhin in der Studie bleibenNew York, USA und Mainz, Deutschland, 18. Februar 2021 — Pfizer Inc. (NYSE: PFE) und BioNTech SE (Nasdaq: BNTX) gaben heute die Behandlung erster Teilnehmerinnen in einer globalen Phase-2/3-Studie bekannt, um die Sicherheit, Verträglichkeit und Wirksamkeit des Pfizer-BioNTech COVID-19-Impfstoffs (BNT162b2) zur Vorbeugung von COVID-19 in gesunden, schwangeren Frauen ab 18 Jahren zu untersuchen.„Wir sind stolz darauf, diese Impfstoffstudie...